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ABSTRACT 
Background. There is a high prevalence of liver 
disease among the recipients of organs from donors 
with antibodies to hepatitis C virus (HCV). We un- 
dertook a study to determine the frequency of per- 
sistent HCV infection, as indicated by the presence of 
HCV RNA, among both cadaveric organ donors positive 
for antibodies to HCV (anti-HCV) and the recipients of 
organs from these donors. 
Methods. Serum samples from donors and recipients 
were tested for HCV RNA with the reverse tran- 
scriptase polymerase chain reaction, with use of 
primers from the 5' untranslated region of the HCV 
genome, and for anti-HCV with the first-generation 
enzyme-linked immunosorbent assay (ELISA) and two 
second-generation tests. 
Results. HCV RNA was detected in 9 of 11 organ 
donors (82 percent) with a positive first-generation 
ELISA for anti-HCV. Among the organ recipients, the 
prevalence of HCV RNA increased after transplan- 
tation: 7 of 26 patients (27 percent) had positive 
samples before transplantation, as compared with 23 of 
24 patients (96 percent) after transplantation 
(P < 0.001). Among 13 recipients who were HCV RNA- 
negative before receiving organs from the nine HCV 
RNA-positive donors, HCV infection was detected in 
all 13 after transplantation, and anti-HCV developed in 
8 (62 percent). On the basis of a positive test for HCV 
RNA, the maximal sensitivity of the three anti-HCV 
tests was 57 percent (positive in 4 of 7 patients with 
end-stage organ failure) before transplantation and 70 
percent (positive in 16 of 23 patients) after transplan- 
tation. 
Conclusions. Nearly all the recipients of organs from 
anti-HCV-positive donors become infected with HCV. 
The current tests for anti-HCV antibodies underes- 
timate the incidence of transmission and the preva- 
lence of HCV infection among immunosuppressed 
organ recipients. 
Roth D, Fernandez JA, Babischkin S, De Mattos A, Buck BE, 
Quan S,  Olson L, et al. Detection of hepatitis C virus infection 
among cadaver organ donors: evidence for low transmission of 
disease. Ann Intern Med 1992;117:1705-1709. 
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ABSTRACT 
Objective: To determine the prevalence of antibodies 
to hepatitis C virus (anti-HCV) and HCV RNA among 
cadaver organ donors and to correlate these results 
with donor liver histologic abnormalities and evidence 
for transmission of disease through organ transplan- 
tation. 
Design: Retrospective testing of stored serum 
samples from cadaver organ donors for anti-HCV and 
HCV RNA. 
Setting: Transplantation service of the University of 
Miami/Jackson Memorial Medical Center and other 
cooperative medical centers furnishing follow-up data. 
Subjects: Of 1096 cadaver organ donors harvested 
between 1 January 1979 and 28 February 1991,484 had 
stored serum samples available for analysis. Recipients 
of organs from recombinant immunoblot assay 
(R1BA)-positive donors for whom adequate follow-up 
was available were also included in the analysis. 
Measurements: Samples were tested for anti-HCV by 
enzyme-linked immunosorbent assay (ELISA). Confir- 
matory testing was done using a second-generation 
RIBA. Hepatitis C viral RNA was detected in serum 
using the polymerase chain reaction. Liver biopsies 
were obtained from the organ donor and interpreted 
blindly by a pathologist unaware of the clinical data. 
Liver chemistry profiles and serum sample analysis for 
HCV RNA were done for transplant recipients. 
Results: From the 484 cadaver organ donors, 89 
samples (18%; 95% CI, 15% to 21%) were reactive by 
ELISA. Of these, 33 (6.8%; CI, 4.6% to 9%) were RIBA 
seropositive. Hepatitis C viral RNA sequences were 
detected in 50% of the RIBA-positive serum samples 
tested. Liver tissue was available from 24 of the 33 
RIBA-positive donors and showed chronic active hep- 
atitis in 16, chronic persistent hepatitis in 2, and no 
abnormality in 6. Among the 46 recipients of a kidney 
from a RIBA-positive donor, 13 (28%; CI, 15% to 41%) 
developed post-transplant liver disease, of which only 
4 cases were highly suggestive of viral transmission 
from the donor. Little morbidity and no mortality 
could be attributed to liver disease in this cohort of 
recipients. 
Conclusions: These data suggest that HCV trans- 
mission by organ transplantation is low and that the 
consequences of infection are small. If the medical 
condition of the potential recipient is so serious that 
other options no longer exist, the use of an organ from 
an anti-HCV-seropositive donor should be considered. 
COMMENTS 
When one considers HCV infection and organ trans- 
plantation, two questions call for answers: first, what is 
the actual transmission rate of hepatitis C virus (HCV) 
during transplantation, and second, what are the con- 
sequences of acquisition of HCV for the graft recipient? 
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Previous studies of HCV transmission have been ham- 
pered by the lack of sensitivity and specificity of antibody 
tests for HCV infection (1). Lack of predictive value of 
antibody tests for HCV will result in the destruction of 
many organs that might have been safely used for 
transplantation. Additionally, use of an HCV-infected 
organ may be indicated if the clinical course of HCV 
infection acquired through transplantation is relatively 
benign. There is little doubt that a severe shortage of all 
types of organs for transplantation exists, a shortage 
with real clinical consequences. For example, from 1988 
to 1992 the number of patients awaiting organ trans- 
plantation rose from 13,000 to 24,000, and the number 
of patients per annum who died while waiting for an 
organ rose from 1,500 to 2,500 (2). 
These two studies, by Pereira et al. and Roth et al., 
used detection of HCV RNA by polymerase chain 
reaction (PCR) to definitively determine the presence of 
hepatitis C infection. Each study began with the iden- 
tification of a group of organ donors that were HCV 
antibody (anti-HCW-positive on first-generation 
ELISA. Further studies were made in this group of 
organ donors only. This design created a problem: 
transmission of HCV by donors positive for HCV RNA 
but negative for anti-HCV was not studied. This mode of 
transmission may account for a significant percentage of 
HCV infection after transplantation because HCV 
viremia without detectable anti-HCV is well described. 
Determination of the frequency of transmission of HCV 
from anti-HCV-negative donors awaits prospective 
study. 
Anti-HCV positivity among the donors in these two 
studies was quite different. Pereira et al. found that 13 
(2%) of 716 donors were anti-HCV positive. Of 11 
anti-HCV-positive donors studied, 9 (82%) were HCV 
RNA positive. In Roth’s study 89 (18%) of 484 donors 
were anti-HCV-positive; of these, 33 were positive on 
second-generation recombinant immunoblot assay 
(RIBA) but only 15 were HCV RNA positive. The two 
groups of researchers apparently used the same arbi- 
trary cutoff for the first generation ELISA, Pereira had 
only about two false-positive donors (18%) and Roth had 
roughly 74 false-positive donors (83%). Although major 
differences among antibody assays were noted in the 
evaluation of the donor groups, the final PCR analysis 
gave similar results; 2% and 3% of the donors were HCV 
RNA positive in Pereira’s group and in Roth’s group, 
respectively. These differences illustrate the need for 
highly sensitive yet specific tests for HCV in screening 
organ donors to prevent the inadvertent transmission of 
HCV and the wastage of organs from donors who are not 
infected with the virus. This technology is being de- 
veloped and may soon be available in the form of the 
clinical application of PCR or a chemoluminescent 
branched-chain DNA hybridization assay for the de- 
tection of HCV RNA (being developed by Chiron Corp., 
Emeryville, CAI. 
To evaluate the effect on the recipient of an organ 
from an anti-HCV-positive donor, Pereira et al. used 
PCR to identify HCV RNA in serum of recipients before 
and after transplantation. All HCV RNA-negative re- 
cipients of organs from HCV RNA-positive donors 
became positive for HCV RNA. Of the recipients in 
whom serum HCV RNA was detected after transplan- 
tation, anti-HCV was found in 35% to 70% of cases, 
depending on the test used. No HCV RNA-negative 
recipient who received a HCV RNA-negative organ 
became infected, although such patients were few. The 
type of organ transplanted (heart, liver or kidney) did 
not appear to have an influence on the transmission of 
HCV from an infected donor to a recipient but, again, the 
numbers were small. 
In contrast, Roth et al. have PCR data on donor sera 
only; they do not have PCR confirmation of HCV 
infection in organ recipients. The absence of this “gold 
standard” confounds interpretation of positive or neg- 
ative antibody tests. For example, they found that 13 of 
15 anti-HCV (by R1BA)-negative recipients who re- 
ceived an anti-HCV (by R1BA)-positive organ remained 
RIBA negative after 1 yr. These data led Roth et al. to 
conclude that HCV transmission by organ transplan- 
tation is low and that the consequences of infection are 
small. However, 9 of the 15 recipients received organs 
from HCV RNA-negative donors. Among the six recip- 
ients who received organs from HCV RNA-positive 
donors, only one was RIBA positive during the follow-up 
period. But four of these six recipients had contracted 
chronic hepatitis after 1 yr. The serum HCV RNA data 
from Pereira et al. would suggest that all of these 
recipients with hepatitis in Roth’s study were infected 
with HCV. Data published in abstract by Wreghitt et al. 
(3) support this conclusion. In their study, 14 
patients - who were all anti-HCV-negative before 
transplantation - received organs from donors who were 
anti-HCV-positive on second-generation RIBA. 
Thirteen of these recipients became infected with HCV, 
including eight who remained anti-HCV negative but 
were HCV RNA positive on PCR. It should be mentioned 
that detection of serum HCV RNA is not a foolproof 
measure of HCV infection. Wright et al. (4) found two 
liver transplant recipients without detectable HCV RNA 
in serum who had hepatic HCV RNA. 
More difficult to determine are the long-term clinical 
consequences for patients who receive HCV-infected 
organs. It is probable that a t  least 50% of persons who 
acquire HCV will progress to chronic liver disease, and 
HCV infection may have a significantly different clinical 
course in immunosuppressed transplant patients (5). 
The studies under commentary here do not have 
sufficient lengths of follow-up to answer these questions. 
Nevertheless, the data of Pereira et al. (61, along with 
those of Wright et al. (4) and Poterucha et al. (7) suggest 
that it is premature to dismiss HCV infection trans- 
mitted through transplantation or transplantation- 
related blood transfusion as having little clinical impor- 
tance. Thus the current recommendation of the UNOS 
Ad Hoc Donations Committee to eschew kidney grafts 
from donors with active viral hepatitis seems prudent 
(2). 
Liver transplant recipients are at greater risk of HCV 
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transmission at the time of transplantation because of 
the many units of blood products required at the time of 
surgery. Wright et al. (4) reports that 8 of 17 patients 
who acquired HCV did so after the blood bank began 
screening samples with a first-generation ELISA. The 
average liver recipient received 69 units of blood. Wright 
and others (8-10) have also shown that nearly all liver 
recipients who were infected with HCV before trans- 
plantation reinfected their grafts after transplantation. 
The issue of whether HCV-infected organs can be given 
to anti-HCV-positive recipients is probably more im- 
portant in liver transplant patients. The safety of this 
practice is unknown, but Pereira et al. outline several 
reasons why it may not be safe. Anti-HCV is not 
protective against reinfection with HCV, and the conse- 
quences of reinfection with different strains of HCV are 
unknown. Farci et al. (11) recently demonstrated in 
chimpanzees the lack of protection by HCV antibodies 
against reinfection with the same strain and different 
strains of HCV. But they did observe that in those 
chimpanzees that were viremic in addition to having 
HCV antibodies, attempts to reinfect them with a second 
strain were not successful. Thus the question of trans- 
planting an infected organ into a HCV-viremic indi- 
vidual may be open to further study. 
We draw the following conclusions from our review of 
these recent studies: first, it appears that most recipients 
of organs from HCV-infected donors will become in- 
fected by HCV. Second, detection of HCV RNA by PCR 
should offer a marked improvement over antibody tests 
in identifying donors who are infected. (This conjecture 
was not tested in the studies under commentary.) Third, 
the clinical courses of patients who receive HCV-infected 
organ should be studied further. It seems unduly 
optimistic to consider these infections trivial. Finally, 
the decision to transplant an HCV-infected organ into a 
patient with end-stage organ disease remains a complex 
issue in which possible benefit must be weighed against 
possible harm. The studies under review here emphasize 
the need for measurement of HCV viremia, rather than 
anti-HCV antibodies, as the best method to document 
active HCV infection in potential organ donors and 
recipients. 
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TRANSFORMING GROWTH FACTOR-P1: THERE IS 
REGULATION BEYOND TRANSCRIPTION 
Kim S-J, Park P, Koeller D, Kim KY, Wakefield LM, 
Sporn MB, Roberts AB. Post-transcriptional regulation 
of the human transforming growth factor-pl gene. 
J Biol Chem 1992;267:13702-13707. 
ABSTRACT 
Since many lines of evidence suggest that expression 
of the transforming growth factor-pl (TGF-p1) gene 
may be regulated post-transcriptionally, we examined 
the effect of the 5’-untranslated region (UTR) of this 
gene on TGF-Pl expression. For this purpose, frag- 
ments of the 840-nucleotide highly GC-rich TGF-P1 
5’-UTR were inserted into the 5’-UTR of the structural 
gene for human growth hormone driven by the simian 
virus 40 early promoter. A portion of the 5’-UTR of 
TGF-P1 mRNA spanning the sequences from +11 to 
+ 147 was shown to inhibit growth hormone expression 
by as much as 22-fold. This effect was cell-specific; 
growth hormone production was inhibited in PC-3 
human prostate adenocarcinoma and A-549 human 
lung adenocarcinoma cells, while no effect was seen in 
rat pheochromocytoma PC12 cells, which show effi- 
cient translation of endogenous TGF-p1 mRNA. Com- 
puter analysis showed that this region of the 5’-UTR 
contained a stable secondary stem-loop structure 
spanning sequences + 49 to + 76. This stem-loop region 
alone is sufficient to inhibit expression of the growth 
hormone gene, suggesting that it plays an important 
role in post-transcriptional regulation of TGF-pl gene 
expression. 
COMMENTS 
The transforming growth factor (TGF)-Ps are a family 
of multifunctional peptides that regulate cell prolifer- 
ation, function and differentiation. Hepatologists are 
particularly interested in TGF-PI because of its role in 
